GREEN!! On a day like this. Something is brewing. High Volume too!!
and you know this based on what economic model?
Most antibiotics and many drugs are naturally produced by fungi and drug companies are making billions from these natural products. We all know that Vesele is not being sold for 1K a dose. This is all about OTC Fluti
What exactly did they present last week? Where is the link? Not only did they not impress but they must have presented something that shows worthlessness of BL-8040. ?? Any link? Need a link since the worthless CEO does not communicate. How BL-5010?? What kink of revenue should come in from that?
Check out CPXX - a positive phase III = jump from 1.1 to 30 in less than a year. JUST BOUGHT by JAZZ for 1.5 billion.
If CPXX can be bought for 1.5 billion with no FDA approval. PETX = at least 1 billion buyout especially with AT-014, which has unbelievable clinical results for dog cancer
You mean like every developmental stage biotech? Some worth over 20 billion. Not too many of these biotechs worth billions have a near FDA approval and also current revenue. In fact most are Phase 2 or Phase 1 or even just clinical
“In the overall survival analysis, we were intrigued by activity seen with CRS-207 as a single-agent. While the median duration of 5.4 months appears greater for CRS-207, the overall survival curve of CRS-207 alone was comparable to overall survival seen with chemotherapy. Of note, due to a disproportionately high dropout rate in the single-agent chemotherapy arm, most of these patients instead received a variety of combination treatments, including chemotherapies, immunotherapies and targeted therapies,” said Dirk Brockstedt, Ph.D., executive vice president, research and development for Aduro."
Very interesting, their endpoint (with GVAX) was missed but what they did see was that Cr-207 alone (without GVAX) worked a bit better than the best care possibly given to the chemo arm, which was more than chemo and included all sorts of care. This is encouraging actually!!!
Does not look halted. They have stopped recruiting new patients but i see nothing showing a halt
No, they just applied for the possibility of an offering. I see this more as preparing to sell into a massive rally after positive results this year at 80-100/share. They have 440 million in cash, would be absolutely incredibly unbelievably stupid to sell now. Just ridiculous to think that they would right now
Yep. Unfortunately they now be at the point where they will need to dilute the hell out of the shares unless they do something radical and fast. Move out of Israel, get a new CEO. There is serious danger now of delisting. The &^& CEO may have permanently destroyed the stock. Biggest mistake was diluting into the rally last year for a signifiant discount. HUGE mistake. I am afraid a 1 to 10 reverse along with new headquarters is the only option.
They only registered because they know huge news is coming this year, sending the stock to 60 plus. That is a good time to sell shares to the public. Not now and they have absolutely no reason with 430 million in cash. And for earnings, ADRO has no revenues and in development! come on! Plus only missed estimates because milestone payment of 22 million is deferred. Otherwise they would have smoked estimates
This is great news! With the 8040 data, should have been up 400%. Instead down 15%. Need to get out of Israel. But that is another topic.
How much expected rev per year?? What are the royalty rates?? This is no-cost revenue too!! I wonder if it is enough to cover costs of 8040 development before a partner comes in. May also be enough so that an 8040 partner deal is more attractive (i.e. they dont need the cash as desperately now with 5010 rev)